Supplementary Figure S4 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

Key Points

Enhanced understanding of how ferroptosis influences precision therapy in prostate cancer highlights genetic targets.
The identified enhancer variant rs7077830 is linked to increased expression of NCOA4 via ZNF384 regulation.
Multicohort analyses demonstrate the genetic variant's potential impact on therapeutic outcomes in prostate cancer.
Findings suggest that targeting ferroptosis pathways could improve precision therapy strategies for prostate cancer.

We only have this paper's title and publication details.

Integrated analyses reveal that an enhancer variant impacts ferroptosis in prostate cancer, suggesting potential precision therapy pathways.

ZNF384 regulates NCOA4 through binding to the mutant allele of rs7077830.

No takes yet. Share an insight, caveat, or question.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share